BACKGROUND: The rapid increase of HIV-1 strains resistant to current antiretroviral drugs is a challenge for successful AIDS therapy. This necessitates the development of novel drugs, and to this end, availability of screening systems for in vitro drug discovery is a priority. Herein, we report the modification of a previously developed system for increased sensitivity, ease of use, and cost-efficiency, based on the application of the EGFP marker. METHODS: A PCR-amplified gfp gene (gfp) was cloned into pmzNL4-3, the plasmid already designed to produce single-cycle replicable virions, in frame with the reverse-transcriptase gene to construct the pmzNL4-3/GFP plasmid. GFP-mzNL4-3 pseudo-typed virions, as the first progeny viruses, were recovered from the culture supernatant of HEK293T cells co-transfected with pmzNL4-3/GFP and the helper plasmids pSPAX2 and pMD2G, which respectively encode HIV-1 Gag-Pol and vesicular stomatitis virus glycoprotein. Single-cycle replication and virion production were assessed by syncytia formation, p24 antigen assays, and electron and fluorescence microscopy. RESULTS: The incorporation of EGFP into the viral particles allowed their quantification by fluorometry, flow-cytometry, and fluorescence microscopy; however, this modification did not affect the single-round infectivity or production rate of the GFP fluorescence-emitting virions. CONCLUSIONS: Our results certify the development of a rapid, inexpensive, and safe GFP-reporting single-cycle replicable system for anti-HIV drug discovery. Further experiments are needed to measure the validity and robustness of the assay.
BACKGROUND: The rapid increase of HIV-1 strains resistant to current antiretroviral drugs is a challenge for successful AIDS therapy. This necessitates the development of novel drugs, and to this end, availability of screening systems for in vitro drug discovery is a priority. Herein, we report the modification of a previously developed system for increased sensitivity, ease of use, and cost-efficiency, based on the application of the EGFP marker. METHODS: A PCR-amplified gfp gene (gfp) was cloned into pmzNL4-3, the plasmid already designed to produce single-cycle replicable virions, in frame with the reverse-transcriptase gene to construct the pmzNL4-3/GFP plasmid. GFP-mzNL4-3 pseudo-typed virions, as the first progeny viruses, were recovered from the culture supernatant of HEK293T cells co-transfected with pmzNL4-3/GFP and the helper plasmids pSPAX2 and pMD2G, which respectively encode HIV-1Gag-Pol and vesicular stomatitis virus glycoprotein. Single-cycle replication and virion production were assessed by syncytia formation, p24 antigen assays, and electron and fluorescence microscopy. RESULTS: The incorporation of EGFP into the viral particles allowed their quantification by fluorometry, flow-cytometry, and fluorescence microscopy; however, this modification did not affect the single-round infectivity or production rate of the GFP fluorescence-emitting virions. CONCLUSIONS: Our results certify the development of a rapid, inexpensive, and safe GFP-reporting single-cycle replicable system for anti-HIV drug discovery. Further experiments are needed to measure the validity and robustness of the assay.
Entities:
Keywords:
Drug discovery; EGFP; Fluorometry; HIV-1; Single-round infection
Authors: Christina Ochsenbauer-Jambor; Jennifer Jones; Marintha Heil; Kenneth P Zammit; Olaf Kutsch Journal: Biotechniques Date: 2006-01 Impact factor: 1.993
Authors: R Zabihollahi; S M Sadat; R Vahabpour; M R Aghasadeghi; A Memarnejadian; T Ghazanfari; M Salehi; A Rezaei; K Azadmanesh Journal: Acta Virol Date: 2011 Impact factor: 1.162
Authors: Tulio de Oliveira; Susan Engelbrecht; Estrelita Janse van Rensburg; Michelle Gordon; Karen Bishop; Jan zur Megede; Susan W Barnett; Sharon Cassol Journal: J Virol Date: 2003-09 Impact factor: 5.103
Authors: Martin E Adelson; Annmarie L Pacchia; Malvika Kaul; Robert F Rando; Yacov Ron; Stuart W Peltz; Joseph P Dougherty Journal: Antimicrob Agents Chemother Date: 2003-02 Impact factor: 5.191
Authors: A J Japour; D L Mayers; V A Johnson; D R Kuritzkes; L A Beckett; J M Arduino; J Lane; R J Black; P S Reichelderfer; R T D'Aquila Journal: Antimicrob Agents Chemother Date: 1993-05 Impact factor: 5.191
Authors: Venice Du Pont; Christoph Wirblich; Jeong-Joong Yoon; Robert M Cox; Matthias J Schnell; Richard K Plemper Journal: J Virol Date: 2020-06-16 Impact factor: 5.103
Authors: Ignacio Rodríguez-Izquierdo; Daniel Sepúlveda-Crespo; Jose María Lasso; Salvador Resino; Ma Ángeles Muñoz-Fernández Journal: Wiley Interdiscip Rev Nanomed Nanobiotechnol Date: 2022-01-12